Patent office

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review

Retrieved on: 
Wednesday, March 27, 2024
Professional Services, Health, Neurology, Legal, Finance, General Health, Pharmaceutical, PGR, Plasma, Medication, Patent, Patient, Ganaxolone, PTAB, IPR, Marinus, Pharmacology, Inter partes review, Patent office, Therapy, Epilepsy, Status epilepticus, Pharmaceutical industry

This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).

Key Points: 
  • This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refractory status epilepticus (RSE).
  • “Over the past two decades, Marinus has invested more than $100 million into our ganaxolone development programs in SE,” stated Dr. Scott Braunstein, Chairman and CEO of Marinus.
  • We believe this Ovid challenge is without merit and is an unfortunate distraction to the important work we do at Marinus.
  • In response to Marinus’ request for PGR, Ovid abandoned 23 of the 31 claims in its patent.

USPTO Examiner Affirms Rejection of Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

Retrieved on: 
Wednesday, March 6, 2024
Professional Services, Patent Law, Medical Devices, Health, Legal, Biotechnology, Patent office, Infection, Court, Patent, Patient, United States patent law

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has issued a Reexamination Advisory Action regarding the relevant claims of the ‘483 patent that Magnolia Medical asserted against the Kurin Lock product.

Key Points: 
  • Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has issued a Reexamination Advisory Action regarding the relevant claims of the ‘483 patent that Magnolia Medical asserted against the Kurin Lock product.
  • The Patent Office found that Magnolia’s arguments regarding claims 1 and 24 do not overcome its prior final rejection of these claims, and noted that any finally rejected claims will be cancelled.
  • “Magnolia Medical continues to abuse the legal system and the patent continuation process in an attempt to use the Courts and USPTO to do what it cannot do in the marketplace.
  • Kurin passively sidelines potential contaminants during blood culture collection.

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Retrieved on: 
Tuesday, February 20, 2024
Patent office, Fast Track, Therapy, Fibrosis, Doctor of Philosophy, Orphan drug, PSC, Inflammation, TEL, FDA, Patent, Treatment, Use, Primary sclerosing cholangitis, Composition, Liver transplantation, CMMB, Chemokine, Liver, CCL24, Antibody, Pharmaceutical industry

TEL AVIV, Israel, Feb. 20, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation. CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC). Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.

Key Points: 
  • CM-101 is currently being assessed in the global Phase 2 SPRING trial for the treatment of primary sclerosing cholangitis (PSC).
  • Patient enrollment in the trial has been completed, with a topline data readout expected midyear 2024.
  • In clinical and preclinical studies, this distinctive approach has been shown to inhibit fibrogenesis and interfere with core PSC pathways.
  • and the FDA recently awarded CM-101 Fast Track designation for the treatment of PSC in adults.

Miller Barondess Expands IP Litigation Practice

Retrieved on: 
Wednesday, November 1, 2023
Professional Services, Legal, Patent Law, Insurance, University of Colorado Law School, Sport, Patent, Arizona State University, Theft, Government, Face, Inter partes review, Intellectual property, United States Court of Appeals for the Federal Circuit, Multimedia, Patent office, LLP, Partnership, Kirkland & Ellis, Sandra, University, Health, Lawyer, 3D printing, IP

Miller Barondess, LLP adds top patent and trade secret litigator Ben Herbert to its partnership, continuing the expansion of the firm's Intellectual Property practice.

Key Points: 
  • Miller Barondess, LLP adds top patent and trade secret litigator Ben Herbert to its partnership, continuing the expansion of the firm's Intellectual Property practice.
  • Adding his patent expertise to the IP team further enhances the firm's already robust IP practice and solidifies its position as a powerhouse in IP litigation.
  • "We are very pleased to have Ben working with us as the firm continues to grow," said Skip Miller, a founding partner of Miller Barondess.
  • Miller Barondess is a Los Angeles-based firm specializing in litigation, trial, and appellate work in California and around the country.

Sterne Kessler Honored as US Post-Grant Firm of the Year at Global IP Awards

Retrieved on: 
Friday, October 20, 2023
Sterne, Publication, WTR, Patent office, Lawyer, World Trademark Review, Tier 1, Intellectual Asset Management, Goldstein, IAM, Patexia, Patent Trial and Appeal Board, PTAB, Pharmaceutical industry, Patent

The Global IP Awards, organized by leading intellectual property publications Intellectual Asset Management (IAM) and World Trademark Review (WTR), recognize the outstanding achievements of law firms and their lawyers in litigation, prosecution, and transactional work.

Key Points: 
  • The Global IP Awards, organized by leading intellectual property publications Intellectual Asset Management (IAM) and World Trademark Review (WTR), recognize the outstanding achievements of law firms and their lawyers in litigation, prosecution, and transactional work.
  • The firm also earned top tier recognition in Managing IP 2023 "IP Stars" guide , which ranked the firm in "Tier 1" for PTAB litigation.
  • I am extremely proud of our PTAB trials team for their accomplishments and for winning this and other recent awards.
  • We have a deep bench of talent poised for ongoing success in the years ahead," added Sterne Kessler Managing Director Michael B. Ray .

USPTO Rejects Patent Claims Asserted by Magnolia Medical, Inc. against Kurin, Inc.

Retrieved on: 
Tuesday, August 15, 2023
Medical Devices, Health, Patent Law, Professional Services, Legal, Patent, Patent office, Infection, United States patent law, Invention, Patient, Court, Pharmaceutical industry, Kurin

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin.

Key Points: 
  • Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin.
  • The Patent Office determined that multiple examples of prior art render claims 1 and 24 unpatentable.
  • “We are pleased, but not surprised, to see this action from the USPTO,” said Bob Rogers, CEO of Kurin, Inc. “We strongly believe that we do not infringe the ‘483 patent, but also believe the patent was preceded by other inventions that should render it invalid.
  • This first office action suggests that the Patent Office confirms our belief.

Delaware District Court Permits NanoString’s Counterclaims that 10x Genomics and Harvard Violated the Antitrust Laws

Retrieved on: 
Tuesday, July 11, 2023
Legal, Research, Public Relations, Investor Relations, Communications, Professional Services, Health, General Health, Other Science, Science, Patent office, Genomics, United States patent law, Harvard College, Harvard University, Bangladesh Technical Education Board, Government, District court, Patent, Fellows, NanoString Technologies, Court, Sąd rejonowy, 10x, NIH, Pharmaceutical industry

In its order, the Court granted NanoString’s motion to add new counterclaims for antitrust and unfair competition violations as well as the affirmative defense of “unclean hands” by 10x and Harvard.

Key Points: 
  • In its order, the Court granted NanoString’s motion to add new counterclaims for antitrust and unfair competition violations as well as the affirmative defense of “unclean hands” by 10x and Harvard.
  • On June 6, the Delaware District Court issued an order granting NanoString’s motion for expedited discovery related to the NIH grant documents.
  • On July 10, the Delaware District Court granted NanoString’s motion to add new counterclaims for antitrust and unfair competition violations as well as the affirmative defense of unclean hands by 10x and Harvard.
  • Furthermore, 10x and Harvard deliberately did not produce the NIH grant documents to NanoString during document discovery, despite requests by NanoString.

Sight Sciences Defeats Invalidity Challenges Filed By Alcon and Ivantis In The U.S. Patent Office

Retrieved on: 
Thursday, March 30, 2023
Patent, Patent office, Sale, Complaint, 1836 U.S. Patent Office fire, Public participation in patent examination, District court, Ivanti, Alcon, Microstate, Record, Patent examiner, Douglas v. U.S. District Court ex rel Talk America, Pharmaceutical industry

MENLO PARK, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported that it defeated all four patent invalidity challenges filed by Alcon and Ivantis in the United States Patent and Trademark Office.

Key Points: 
  • MENLO PARK, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today reported that it defeated all four patent invalidity challenges filed by Alcon and Ivantis in the United States Patent and Trademark Office.
  • On August 1, 2022, the Company filed an amended complaint adding Alcon Inc., Alcon Vision, LLC and Alcon Research, LLC as defendants and added allegations of infringement of U.S. Patent No.
  • Ivantis and Alcon responded to the Company’s lawsuit by filing petitions for inter partes review with the U.S. Patent Office seeking the invalidation of U.S. Patent Nos.
  • A five-day jury trial regarding Sight Sciences’ patent infringement claims against Alcon and Ivantis is scheduled to commence in Wilmington, Delaware on April 8, 2024.

Treace Files Patent Infringement Suit To Protect Lapiplasty® Bunion Technology

Retrieved on: 
Monday, March 28, 2022
United States Patent and Trademark Office, Bunion, Investment, District court, Globe, CEO, District, LLC, Technology, Patent office, Patent, Surgeon, Intellectual property, GLOBE, Solution, Patient, Foot, Partnership, 3D printing, TREAC

Treaces lawsuit also alleges copyright infringement, infringement of Treaces trademark rights and unfair competition.

Key Points: 
  • Treaces lawsuit also alleges copyright infringement, infringement of Treaces trademark rights and unfair competition.
  • The suit was filed in the United States District Court for the District of Arizona, seeking injunctive relief and damages.
  • Treaces Lapiplasty 3D Bunion Correction system is the gold standard for the surgical treatment of bunions, said John T. Treace, CEO, Founder and Board Member of Treace.
  • Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction.

TUT Fitness Group Wins Four New Patents Throughout Europe

Retrieved on: 
Wednesday, January 26, 2022
Online, Marketing, Joint, European Patent Office, Pressure, Rubber industry in Malaysia, European Patent Convention, Tendon, European patent law, VP, TUT, Twitter, Exercise, Rowing (sport), Patent office, Instagram, Domestic international sales corporation, Corporate video, LinkedIn, Patent, Technology, YouTube, Partnership, Television, Video game console, BC, Facebook

European Patent Office Officially Grants Patents for TUT TrainerExercise Device in France, Germany, Great Britain and Spain

Key Points: 
  • European Patent Office Officially Grants Patents for TUT TrainerExercise Device in France, Germany, Great Britain and Spain
    TUT Fitness Group is officially granted patents in France, Germany, Great Britain, Spain, and the European Patent Office
    VANCOUVER, BC, Jan. 26, 2022 /PRNewswire/ - TUT Fitness Group Inc .
  • TUT Fitness products feature internationally patented, stackable, TUT Plates resistance bands as the core element in both its TUT Trainer Tower and TUT Rower.These color-coded resistance bands have been laboratory-tested to at least 10,000 cycles without any performance loss, and have a lifetime warranty.
  • "We're very pleased that the Patent Offices in Europe have recognized our technology innovation and awarded us patent protection as we expand sales and distribution of TUT Fitness products throughout Europe."
  • TUT Fitness Group is marketing and selling its patented exercise devices into a $10.7 billion market for home gym equipment.